Oral Allergy Medication For Emergencies - Aquestive Therapeutics' Investigational Therapy Works Even With Exposure To Liquids Of Different Temperatures, Data Shows
Portfolio Pulse from Vandana Singh
Aquestive Therapeutics Inc (NASDAQ:AQST) released topline pharmacokinetic data for its investigational product Anaphylm, an orally administered epinephrine prodrug for severe allergic reactions. The study showed no significant difference in drug absorption based on temperature and pH changes. The company plans to complete supportive studies and request a pre-NDA meeting with the FDA in Q3 2024.
June 25, 2024 | 5:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Aquestive Therapeutics released promising PK data for Anaphylm, showing no significant absorption differences with temperature and pH changes. The company is on track to complete supportive studies and plans to request a pre-NDA meeting with the FDA in Q3 2024.
The release of positive PK data and the company's progress towards FDA approval are likely to boost investor confidence and positively impact AQST's stock price in the short term. The news indicates that Anaphylm could become a significant product in the market for severe allergic reactions.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100